LJI Wealth Management LLC Makes New Investment in Boston Scientific Corporation $BSX

LJI Wealth Management LLC bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 3rd quarter, Holdings Channel.com reports. The institutional investor bought 8,220 shares of the medical equipment provider’s stock, valued at approximately $803,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after purchasing an additional 2,545,381 shares during the period. State Street Corp lifted its stake in Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after buying an additional 713,379 shares during the last quarter. Geode Capital Management LLC lifted its stake in Boston Scientific by 2.0% in the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after buying an additional 622,602 shares during the last quarter. Norges Bank bought a new position in shares of Boston Scientific during the second quarter worth about $2,089,937,000. Finally, Invesco Ltd. increased its holdings in shares of Boston Scientific by 1.4% in the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after acquiring an additional 226,578 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

BSX opened at $88.13 on Friday. The business has a 50 day moving average price of $96.90 and a two-hundred day moving average price of $100.29. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The company has a market capitalization of $130.65 billion, a price-to-earnings ratio of 47.13, a price-to-earnings-growth ratio of 1.56 and a beta of 0.67. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the subject of a number of analyst reports. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday. Truist Financial cut their price target on Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Barclays increased their price objective on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Cowen restated a “buy” rating on shares of Boston Scientific in a research report on Thursday, December 11th. Finally, BTIG Research reiterated a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Friday, November 21st. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $123.89.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

Insiders Place Their Bets

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 93,095 shares of company stock worth $9,305,450. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.